Erythropoiesis-stimulating agents: dose and mortality risk

Area of Science:

• Nephrology
• Hematology
• Clinical Medicine

Background:

• Hypo-responsiveness to erythropoiesis-stimulating agents (ESAs) is linked to higher mortality in end-stage renal disease (ESRD) patients.
• The reasons for this association, whether due to high ESA dosage or underlying conditions causing ESA resistance, remain unclear.

Purpose of the Study:

• To investigate the relationship between erythropoiesis-stimulating agents (ESAs) dosage and all-cause mortality in incident hemodialysis patients.
• To explore the correlation between ESA dosage, hemoglobin levels, and survival outcomes.

Main Methods:

• Retrospective evaluation of 28 incident hemodialysis patients from 2008 to death or December 2011.
• Patients were divided into high and low mean annual ESA dosage cohorts.
• Correlation analysis using Spearman's rho test and survival assessment via Kaplan-Meier curves.

Main Results:

• High-dose ESA therapy was significantly associated with increased all-cause mortality (P = .047).
• A strong negative correlation was observed between ESA dose and hemoglobin levels (rho = -0.825; P < .001).
• Higher ESA dosage in hemodialysis patients correlated with increased mortality risk.

Conclusions:

• Higher erythropoiesis-stimulating agents (ESA) dosage in incident hemodialysis patients is associated with a greater risk of mortality.
• Both ESA dosage and hemoglobin levels appear inversely correlated with mortality, suggesting a potential independent or interactive adverse effect.